Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates

01:19pm, Friday, 24'th Jun 2022 Zacks Investment Research
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
"Can't go wrong" is a serious standard, but a few solid companies really do rise to the meaning of the phrase.

3 Dow Stocks to Buy for a Bear Market

12:30pm, Friday, 24'th Jun 2022
Investors can find safety from the bear market in these three Dow stocks. They offer low volatility, stable dividends and outperformance.

3 Stocks That Drove the Dow's Nearly 200-Point Gain

08:55pm, Thursday, 23'rd Jun 2022 The Motley Fool
Investors seem to be adapting to the reality of a recession on the horizon.
These are 6 dividend income stocks with better yields than the S&P 500. These 6 stocks outperformed the S&P 500 this year and have higher yields, with earnings that can cover the dividends, making the

Merck's (MRK) Pneumococcal Vaccine Gets FDA Nod for Kids

12:39pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Merck (MRK) Gains As Market Dips: What You Should Know

09:45pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Merck (MRK) closed the most recent trading day at $89.16, moving +1.28% from the previous trading session.

The Dow Lost Ground as Investors Piled into Recession-Proof Stocks

08:45pm, Wednesday, 22'nd Jun 2022 The Motley Fool
Market participants think the economy could be in for a tough time.

3 High-Yielding Dividend Stocks to Get You Through the Bear Market

03:30pm, Wednesday, 22'nd Jun 2022 The Motley Fool
These stocks also make for fantastic long-term investments.

Iovance (IOVA) Pipeline Aids Growth Amid Lack of Marketed Drugs

02:48pm, Wednesday, 22'nd Jun 2022 Zacks Investment Research
Iovance (IOVA) is progressing well with the clinical development of its pipeline candidates. It expects to file a BLA with the FDA, seeking approval for its lead candidate to treat metastatic melanoma
Could these pharmaceutical stocks be worth watching today?

3 Stocks That Drove the Dow's 641-Point Gain

08:57pm, Tuesday, 21'st Jun 2022 The Motley Fool
Investors seemed to take a breather today after all of the selling last week.

3 Stocks That Drove the Dow's 641-Point Gain

04:57pm, Tuesday, 21'st Jun 2022
Investors seemed to take a breather today after all of the selling last week.

A Trio of Stocks for Growth-Oriented Investors

12:16pm, Tuesday, 21'st Jun 2022
Growth-oriented investors may want to consider the following stocks, since they represent businesses with price-earnings ratios below 20 that recorded significant improvements in their trailing 12-mon
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE